Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Pitching New Product: A Fund For Tropical Disease Research

Executive Summary

Novartis executive Paul Herrling has been on a whirlwind promotional tour the past few weeks. He's met with government leaders in China, Germany and the Netherlands, and academicians at Yale University, Columbia University and the New York Academy of Sciences. His goal: convincing them to support a new way to fund research on medicines for tuberculosis, dengue fever and other neglected tropical diseases

You may also be interested in...



R&D For Diseases Of Developing Countries Could Be Driven By Pooled Funds

WHO committee backs use of pooled funds to finance R&D, nixes priority review vouchers and finds no need for data exclusivity. Novartis’ Paul Herrling, a committee member, notes that governments would be responsible for R&D costs.

FDA Awards First-Ever Priority Review Voucher To Novartis For Coartem Approval

Coartem clears FDA for acute, uncomplicated malaria; agency finds it effective in regions where people are resistant to chloroquine.

GSK Wades Into The Pooled Approach To Tropical Disease Research

GlaxoSmithKline CEO Andrew Witty's proposal for companies to pool their patents to develop medicines for neglected tropical diseases is a somewhat unusual call for collaboration in the pharmaceutical industry, but not entirely without precedent

Related Content

Topics

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel